Karo Pharma AB announces a recommended voluntary cash offer to acquire all shares in Weifa ASA
· Cash offer at NOK 35 per Weifa share valuing the total share capital of Weifa at approximately NOK 1.28 billion on a fully diluted basis · Recommended by the Board of Directors of Weifa · Pre-acceptances of the Offer from shareholders together representing approximately 45.35% of the issued share capital of Weifa and purchase agreements with holders of 1,735,716 share options Karo Pharma AB (publ) (“Karo Pharma”) and Weifa ASA (“Weifa”; OSE: WEIFA) today announced a transaction agreement whereby Karo Pharma, will launch a recommended voluntary cash offer (the “Offer”) to